冠状动脉支架平台的演变:当前使用的药物排泄支架的简要概述
Pierre Brami1,2, Quentin Fischer1, Vincent Pham1
1Department of Cardiology, Cochin Hospital, Hôpitaux Universitaire Paris Centre, Assistance Publique des Hôpitaux de Paris, 75014 Paris, France.
Journal of clinical medicine
|November 14, 2023
概括
药物排泄支架 (DES) 对心血管疾病进行了显著的先进的穿皮冠状动脉干预 (PCI),从裸金属支架演变为改进的第三代DES,以改善患者的治疗结果和减少并发症.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 心血管疾病是全球主要的死亡原因.
- 穿皮冠状动脉干预 (PCI) 除了医疗治疗外,还可以改善患者的预后.
- 冠状动脉支架技术已经发展,以解决诸如支架静止症和支架血栓症等并发症.
研究的目的:
- 审查冠状动脉药物释放支架 (DES) 平台的历史演变.
- 提供当前DESs临床研究的最新情况.
- 详细说明常用的DES的主要特征.
主要方法:
- 关于冠状动脉支架技术进步的文献综述.
- 对第一代至第三代DES的临床研究分析.
- 综合了关于DES聚合物的生物相容性和效率的数据.
主要成果:
- DES已经从裸金属支架发展到先进的,更薄的,第三代平台.
- 在较新的DES中提高了聚合物生物相容性,提高了效率.
- 了解不良事件推动了DES技术的改进.
结论:
- 冠状动脉支架技术,特别是DES,一直在不断创新.
- 第三代DES在治疗心血管疾病方面取得了重大进展.
- 目前正在进行的研究正在完善DES平台,以获得更好的临床结果.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
535
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
535
Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Acute Coronary Syndrome I: Introduction
30
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
30
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11


